Interestingly, the number of CD45+/FSP-1+ cells was significantly higher in the tumour from patients who received bevacizumab-containing chemotherapy before the surgery compared with the tumour from the patients who received chemotherapy alone or who received no prior therapy (Fig. 8a–c). This evidence concerns the gene PTPRC and neoplasm.